The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.

Saved in:
Bibliographic Details
Title: The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.
Authors: Blevins JE; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States.; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States., Honeycutt MK; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Slattery JD; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Goldberg M; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Rambousek JR; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Tsui E; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Dodson AD; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Shelton KA; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States., Salemeh TS; Seattle Children's Research Institute, Seattle, WA, United States., Elfers CT; Seattle Children's Research Institute, Seattle, WA, United States., Chichura KS; Department of Chemistry, Syracuse University, Syracuse, NY, United States., Ashlaw EF; Department of Chemistry, Syracuse University, Syracuse, NY, United States., Zraika S; VA Puget Sound Health Care System, Office of Research and Development Medical Research Service, Department of Veterans Affairs Medical Center, Seattle, WA, United States.; Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States., Doyle RP; Department of Chemistry, Syracuse University, Syracuse, NY, United States.; Departments of Medicine and Pharmacology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States., Roth CL; Seattle Children's Research Institute, Seattle, WA, United States.; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.
Source: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jul 22; Vol. 15, pp. 1432928. Date of Electronic Publication: 2024 Jul 22 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-2392
DOI:10.3389/fendo.2024.1432928